评估老年人中不同eGFR方程的长期结局
该队列研究基于ASPREE试验及其随访数据,比较了在社区居住的老年人中,使用针对老年人群验证的BIS1和EKFC方程替代2021 CKD-EPI肌酐方程对CKD分期和长期结局的影响。结果显示,BIS1和EKFC方程使eGFR值降低12-15 ml/min/1.73 m2,CKD患病率从21%升至37%-46%,但重新分类组与非重新分类组的长期结局相似;无论使用哪种方程,降低的无残疾生存、全因死亡或MACE风险主要出现在eGFR低于45 ml/min/1.73 m2时。
要点
- BIS1和EKFC方程较CKD-EPI2021方程显著降低eGFR值并提高CKD患病率。
- 使用老年验证方程重新分类CKD分期并未识别出额外的高风险个体。
- 不良结局风险主要集中于eGFR低于45 ml/min/1.73 m2,与方程无关。
核心结论
- 使用老年验证方程会大幅增加CKD患病率,但可能无法识别额外的高风险个体。
- 当前CKD诊断阈值在老年人中可能不适用,尤其当应用老年验证方程时。
- 需要重新考虑衰老背景下的CKD定义。
研究设计与样本
- 队列研究,使用ASPREE试验及其观察性随访(ASPREE-eXtension)的数据。
- 纳入17,686名社区居住的老年人,平均年龄75.1±4.3岁。
- 采用生存分析比较从CKD-EPI2021方程转换为BIS1或EKFC方程后CKD分期重新分类组与未重新分类组的结局风险。
- 使用限制性立方样条分析eGFR与健康结局的关联,参考eGFR为75 ml/min/1.73 m2。
主要发现
- BIS1和EKFC方程得出的eGFR值比CKD-EPI2021低12至15 ml/min/1.73 m2。
- CKD患病率从21%增加至37%-46%。
- 大多数参与者在从CKD-EPI2021转换为BIS1或EKFC时CKD分期升高。
- 重新分类组与非重新分类组的长期结局相似。
- 在所有方程中,降低的无残疾生存、全因死亡或MACE风险主要出现在eGFR低于45 ml/min/1.73 m2时,且不依赖于尿白蛋白-肌酐比值(uACR)。
关键数值与推荐
- CKD诊断阈值:eGFR < 60 ml/min/1.73 m2(当前标准)。
- 年龄适应CKD定义:eGFR < 45 ml/min/1.73 m2。
- BIS1和EKFC方程较CKD-EPI2021方程eGFR值低12-15 ml/min/1.73 m2。
- CKD患病率从21%升至37%-46%。
临床怎么用
- 在老年人中应用老年验证的eGFR方程时,需注意CKD患病率可能显著增加。
- 重新分类至更高CKD分期并不一定意味着更高的短期风险,临床决策应结合其他因素。
- eGFR低于45 ml/min/1.73 m2可能作为老年人风险分层的更合适阈值。
局限性
- 研究基于ASPREE试验人群,可能限制普遍性。
- 未报告其他潜在混杂因素的详细控制情况。
- 未涉及不同方程在特定亚组中的表现差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The current diagnostic threshold for chronic kidney disease (CKD; estimated glomerular filtration rate [GFR; eGFR] < 60 ml/min per 1.73 m2) may lead to overdiagnosis in older adults. Additionally, no consensus exists regarding the optimal eGFR equation for use in older adults, despite considerable variability in calculations between equations. We investigated the impact of using eGFR equations validated for older populations (Berlin Initiative Study 1 [BIS1] and European Kidney Function Consortium [EKFC]) in place of the 2021 CKD-Epidemiology collaboration (EPI) creatinine equation (CKD-EPI2021) and assessed the implications of an age-adapted CKD definition (eGFR < 45 ml/min per 1.73 m2). METHODS: This cohort study used data from the aspirin in reducing events in the elderly (ASPREE) trial and its observational follow-up (ASPREE-eXtension). ASPREE enrolled community-dwelling older adults. Separate survival analyses compared the risk of reduced disability-free survival (DFS), its components, or major adverse cardiovascular events (MACE) between participants reclassified to a different CKD stage versus those who remained within the same stage when changing from CKD-EPI2021 to BIS1EKFC. Associations between eGFR and health outcomes were analyzed using restricted cubic splines referenced to eGFR of 75 ml/min per 1.73 m2. RESULTS: Among 17,686 participants (mean age 75.1 ± 4.3 years), BIS1, and EKFC yielded eGFR values 12 to 15 ml/min per 1.73 m2 lower than CKD-EPI2021; increasing CKD prevalence from 21% to 37%-46%. Most participants moved to a higher CKD stage when changing from CKD-EPI2021 to BIS1, or EKFC; however, long-term outcomes were similar across reclassified and nonreclassified groups. Across all equations, risks of reduced DFS, all-cause mortality, or MACE were observed primarily below eGFR 45 ml/min per 1.73 m2, independent of urine albumin-creatinine ratio (uACR). CONCLUSION: The use of older-age validated equations would substantially increase the prevalence of CKD but may not identify additional individuals at higher risk. These results suggest that current diagnostic thresholds may not be appropriate for older adults, particularly when applying older-age validated equations, and underscore the need to reconsider CKD definitions in the context of aging.
引用
- Bongetti EK, Wolfe R, Orchard SG, et al. Evaluating Long-Term Outcomes Across eGFR Equations in Older Adults. Kidney Int Rep. 2026. PMID: 42027555. doi:10.1016/j.ekir.2026.106487
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。